Shattuck Labs (STTK) Operating Income (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Operating Income of -$15.5 million for Q1 2026, down 8.03% year-over-year from -$16.9 million in Q1 2025, and down 16.26% quarter-over-quarter from -$13.4 million in Q4 2025.
Analysis
Shattuck Labs (STTK) Operating Income (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Operating Income for 8 consecutive years, with -$15.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 8.03% year-over-year to -$15.5 million; the TTM figure through Mar 2026 stood at -$52.7 million (up 29.7% YoY), while the FY2025 annual figure was -$51.5 million, up 36.07% from the prior year.
- Operating Income slipped to -$15.5 million in Q1 2026 per STTK's latest filing, from -$13.4 million in the prior quarter.
- Across five years, Operating Income topped out at -$10.7 million in Q3 2025 and bottomed at -$28.6 million in Q3 2023.
- Historically, Operating Income has averaged -$20.2 million across 5 years, with a median of -$20.0 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Income sank 384.19% — and 2025, when it jumped 43.25%.
- Shattuck Labs' Operating Income stood at -$26.3 million in 2022, then increased by 27.88% to -$19.0 million in 2023, then retreated by 3.64% to -$19.6 million in 2024, then soared by 31.92% to -$13.4 million in 2025, then fell by 16.26% to -$15.5 million in 2026.
- Business Quant data shows STTK's Operating Income at -$15.5 million in Q1 2026, -$13.4 million in Q4 2025, and -$10.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Shattuck Labs | 879.90 Mn | 879.90 Mn | - | -16.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.16 Mn |
| Mar 31, 2026 | -15.55 Mn |
| Dec 31, 2025 | -13.37 Mn |
| Sep 30, 2025 | -10.72 Mn |
| Jun 30, 2025 | -13.03 Mn |
| Mar 31, 2025 | -14.39 Mn |
| Dec 31, 2024 | -19.64 Mn |
| Sep 30, 2024 | -17.92 Mn |
| Jun 30, 2024 | -22.96 Mn |
| Mar 31, 2024 | -20.04 Mn |
| Dec 31, 2023 | -18.95 Mn |
| Sep 30, 2023 | -28.60 Mn |
| Jun 30, 2023 | -22.75 Mn |
| Mar 31, 2023 | -21.66 Mn |
| Dec 31, 2022 | -26.28 Mn |
| Sep 30, 2022 | -25.23 Mn |
| Jun 30, 2022 | -27.66 Mn |
| Mar 31, 2022 | -24.17 Mn |
| Dec 31, 2021 | 9.25 Mn |
| Sep 30, 2021 | -17.58 Mn |